• HOME
  • ABOUT
  • LEUKEMIA
  • CANCER
  • NEUROSCIENCE
  • MEDICAL DISTRIBUTION
    • Medical
  • COVID-19
    • COVID-19 Tests
    • COVID-19 Home Tests
    • COVID-19 Antigen Tests
    • FDA/Legal Disclaimer
  • News & Press articles
  • Medical Blog
  • Infectious Diseases
  • Research
    • Video Demonstration
    • Alercell Research
    • Corporate Presentation
  • Contact
  • Careers
  • More
    • HOME
    • ABOUT
    • LEUKEMIA
    • CANCER
    • NEUROSCIENCE
    • MEDICAL DISTRIBUTION
      • Medical
    • COVID-19
      • COVID-19 Tests
      • COVID-19 Home Tests
      • COVID-19 Antigen Tests
      • FDA/Legal Disclaimer
    • News & Press articles
    • Medical Blog
    • Infectious Diseases
    • Research
      • Video Demonstration
      • Alercell Research
      • Corporate Presentation
    • Contact
    • Careers
  • HOME
  • ABOUT
  • LEUKEMIA
  • CANCER
  • NEUROSCIENCE
  • MEDICAL DISTRIBUTION
    • Medical
  • COVID-19
    • COVID-19 Tests
    • COVID-19 Home Tests
    • COVID-19 Antigen Tests
    • FDA/Legal Disclaimer
  • News & Press articles
  • Medical Blog
  • Infectious Diseases
  • Research
    • Video Demonstration
    • Alercell Research
    • Corporate Presentation
  • Contact
  • Careers

About Alercell

Developing an Opportune Future in Healthcare

Neuroscience

Oncology

 Alercell, Inc., a Montana company is a molecular diagnostics company pioneering novel therapeutics to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in Oncology in-vitro Diagnostic Testing and Neuroscience. The company was founded with the aim of providing more accurate and timely diagnostic tools for cancer patients worldwide.  Alercell is focused on two segments: Oncology & Neuroscience   

Oncology

Neuroscience

Oncology

Alercell Oncology launched in January 2023 Lena Q51 the very first    Leukemia diagnostic test able to detect up to 51 genes mutations.  Genes mutations in Leukemia is a significant biomarker indication of the disease.

Alercell Oncology will launch soon Lena S1, a Lung cancer early diagnostic test based on DNA Methylation



Neuroscience

Neuroscience

Neuroscience

 Alercell Neuroscience aims to create a nanoparticle neural interface for recording and controlling brain activity with the ultimate goal to find solutions for neurodegenerative diseases such as dementia or Alzheimer.

Our mission: Stop it Before it Starts

The Alercell mission is built on the foundation of “stopping it before it starts”. Our genetics based testing is the first line of assault against cancer & leukemia and infectious disease. We utilize cutting edge technology such as DNA sequencing to develop a myriad of rapid testing tools that are used to discover major disease in the earliest stages. Every new innovation grows from a driving principle of prevention through discovery.

The future belongs to those who seize the opportunities created by innovation.


Delos M. Cosgrove, MD

Copyright © 2020 Alercell - All Rights Reserved.

  • Privacy Policy
  • Terms and Conditions

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept